{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:03:10Z","timestamp":1790492590556,"version":"4.1.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.03152","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T04:25:58Z","timestamp":1547699158000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia"],"prefix":"10.3389","volume":"9","author":[{"given":"Ming-Chin","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-I","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Ning","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Wei","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Hong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb Gonshen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/306239a0","article-title":"Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jval.2013.07.004","article-title":"Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence","volume":"16","author":"Oriana","year":"2013","journal-title":"Value Health"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3324\/haematol.13151","article-title":"Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia","volume":"94","author":"Kim","year":"2009","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s12185-010-0565-1","article-title":"Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion","volume":"91","author":"Nagata","year":"2010","journal-title":"Int J Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"E916","DOI":"10.1002\/ijc.27537","article-title":"Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib","volume":"131","author":"Hassold","year":"2012","journal-title":"Int J Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3109\/10428194.2011.647017","article-title":"Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib","volume":"53","author":"Hayashi","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00432-015-2101-4","article-title":"Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia","volume":"142","author":"El","year":"2016","journal-title":"J Cancer Res Clin Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.coi.2017.01.003","article-title":"Targeting NK-cell checkpoints for cancer immunotherapy","volume":"45","author":"Muntasell","year":"2017","journal-title":"Curr Opin Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3389\/fimmu.2016.00492","article-title":"Immunological and translational aspects of NK cell-based antitumor immunotherapies","volume":"7","author":"Shevtsov","year":"2016","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3324\/haematol.2013.101931","article-title":"Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells","volume":"99","author":"Torelli","year":"2014","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","first-page":"864","DOI":"10.4049\/jimmunol.176.2.864","article-title":"The decreased susceptibility of Bcr\/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation","volume":"176","author":"Cebo","year":"2006","journal-title":"J Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1002\/ijc.25233","article-title":"The BCR\/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity","volume":"127","author":"Salih","year":"2010","journal-title":"Int J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/ni.3513","article-title":"Open conformers of HLA-F are high-affinity ligands of the activating NK-cell receptor KIR3DS1","volume":"17","author":"Garcia-Beltran","year":"2016","journal-title":"Nat Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri3370","article-title":"Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution","volume":"13","author":"Parham","year":"2013","journal-title":"Nat Rev Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1084\/jem.187.5.813","article-title":"Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94\/NKG2 confers protection from natural killer cell-mediated lysis","volume":"187","author":"Borrego","year":"1998","journal-title":"J Exp Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/sj.emboj.7600019","article-title":"Unravelling natural killer cell function: triggering and inhibitory human NK receptors","volume":"23","author":"Moretta","year":"2004","journal-title":"EMBO J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/blood-2009-02-206532","article-title":"Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells","volume":"114","author":"Romagne","year":"2009","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3324\/haematol.2015.135301","article-title":"Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells","volume":"101","author":"Ruggeri","year":"2016","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.4049\/jimmunol.178.4.2491","article-title":"Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3","volume":"178","author":"Maneechotesuwan","year":"2007","journal-title":"J Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S10747613(03)002942","article-title":"GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells","volume":"19","author":"Samson","year":"2003","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.4049\/jimmunol.174.4.2152","article-title":"GATA-3 is an important transcription factor for regulating human NKG2A gene expression","volume":"174","author":"Marusina","year":"2005","journal-title":"J Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3389\/fimmu.2017.00699","article-title":"Human CD56(dim)CD16(dim) cells as an individualized natural killer cell subset","volume":"8","author":"Amand","year":"2017","journal-title":"Front Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0022-1759(01)00359-3","article-title":"A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity","volume":"253","author":"Lecoeur","year":"2001","journal-title":"J Immunol Methods"},{"key":"B38","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/ajh.24096","article-title":"Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am J Hematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1073\/pnas.95.9.5199","article-title":"HLA-E is a major ligand for the natural killer inhibitory receptor CD94\/NKG2A","volume":"95","author":"Lee","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"key":"B41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3389\/fimmu.2015.00567","article-title":"Effector functions of natural killer cell subsets in the control of hematological malignancies","volume":"6","author":"Gismondi","year":"2015","journal-title":"Front Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/leu.2011.239","article-title":"NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice","volume":"26","author":"Chen","year":"2012","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood.V96.5.1961","article-title":"Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine","volume":"96","author":"Mellqvist","year":"2000","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1172\/JCI45816","article-title":"Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity","volume":"121","author":"Mamessier","year":"2011","journal-title":"J Clin Invest."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1226720","article-title":"Therapeutic CD94\/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia","author":"McWilliams","year":"2016","journal-title":"Oncoimmunology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/hon.2034","article-title":"Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study","volume":"31","author":"Uchiyama","year":"2013","journal-title":"Hematol Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1158\/2326-6066.CIR-16-0061-T","article-title":"Dasatinib changes immune cell profiles concomitant with reduced tumor growth in several murine solid tumor models","volume":"5","author":"Hekim","year":"2017","journal-title":"Cancer Immunol Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1182\/blood-2008-02-138701","article-title":"Dasatinib suppresses in vitro natural killer cell cytotoxicity","volume":"111","author":"Blake","year":"2008","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.exphem.2008.09.013","article-title":"Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo","volume":"37","author":"Fraser","year":"2009","journal-title":"Exp Hematol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1126\/science.1103478","article-title":"Natural killer cell signaling pathways","volume":"306","author":"Vivier","year":"2004","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3410\/M3-9","article-title":"Natural killer cell-based therapies","volume":"3","author":"Romagne","year":"2011","journal-title":"F1000 Med Rep."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.03152\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T15:39:49Z","timestamp":1573745989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.03152\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2018.03152"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.03152","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"article-number":"3152"}}